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Abstract
Background: Infection with HIV may result in significant neuropsychological impairment, especially in late stage
disease. To date, there have been no cohort studies of the impact of highly active anti-retroviral treatment (HAART)
in South Africa where clade C HIV is predominant.
Methods: Participants in the current study were recruited from a larger study of HIV-associated neurocognitive
disorders (HAND) and included a group of individuals commencing HAART (n = 82). Baseline and one-year
neuropsychological function was assessed using a detailed battery, and summary global deficit scores (GDS)
obtained. Associations with change in GDS were calculated.
Results: Participants had a median CD4 cell count of 166 at baseline and 350 at follow-up. There were significant
difference across groups of GDS severity at baseline with respect to level of education and GDS change at one
year (p = 0.00 and 0.00 respectively). Participants with severe impairment at baseline improved significantly more
than those with lesser degrees of impairment. Significant improvements were observed in the domains of
attention, verbal fluency, motor function, and executive functions. There were unadjusted associations between
GDS change and male gender, lower levels of education, baseline CD4 count and baseline GDS severity. In an
adjusted model, only baseline GDS severity (p = 0.00) remained significant, with a lower level of education nearing
significance (p = 0.05). The overall model was highly significant (p = 00; r-squared = 0.58).
Discussion: In individuals in late stage HIV commencing HAART in South Africa, those with severe baseline
neuropsychological impairment improved significantly more than those less impaired. While improvement across a
number of neuropsychological domains was observed, high rates of impairment persisted.
Conclusions: The effects of HAART and participant variables, such as test experience, require clarification. Studies
with larger comparison groups, and where HIV disease characteristics are needed to establish whether the trends
we identified are clinically meaningful.
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Background
Neuropsychological impairments due to HIV infection
of the CNS are detectable across all disease stages, but
are more prevalent and marked in individuals with more
severe HIV disease [1,2]. Although the use of highly
active anti-retroviral therapy (HAART) has halved the
incidence of HIV-associated dementia (HAD), the preva-
lence remains significant [3]. In addition, milder forms
of HIV-associated neurocognitive disorders are now
known to persist despite the use of HAART [3,4].
Persistent impairment mayb et h er e s u l to fs e v e r a l
interrelated factors, including host genetic vulnerability,
ongoing low grade inflammation within the CNS and
the effects of HAART itself [5]. In addition, it has been
demonstrated that lower CD4 nadirs are associated with
higher rates of neurocognitive impairment [6].
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be initiated before CD4 counts fall to low levels. The
role of HIV subtype or clade is also unclear. The major-
ity of studies investigating HAND and the effects of
HAART have been conducted in settings where clade B
is predominant, while the burden of HIV disease exists
in southern Africa where clade C is prevalent [7]. Pre-
clinical studies have suggested that the presence of a
defect in the dicysteine motif of the HIV clade C tat
protein might reduce the neurotoxic effects of HIV [8].
Clinical reports from both India and South Africa have
now established that clinical disorder is in fact highly
prevalent, despite this hypothesis [9,10]. There are no
studies to date describing the effect of HAART on neu-
ropsychological impairment in South Africa.
Several published studies have reported on neuropsy-
chological improvement following HAART initiation
[11-13]. The end-point of treatment is to return neurop-
sychological function to normal levels following ade-
quate suppression of CNS viral load and related neuro-
inflammation [4]. To date, neuropsychological improve-
ment has been associated with effective peripheral viral
load suppression, CNS penetration effectiveness (CPE)
of HAART regimens, and has been associated with
severity of baseline (or study entry) neuropsychological
function, and possibly also practice effects in cohort stu-
dies [13-16].
The impact of HAART on the CNS has been debated.
A significant literature supports the contention that
regimens of HAART that are able to penetrate the
blood-brain barrier more readily, and in turn adequately
suppress CSF viral load, are associated with better neu-
ropsychological outcomes [14,17,18]. However, some lit-
erature supports the notion that HAART regimens with
higher CNS penetration effectiveness (CPE) may result
in neuropsychological impairment [16,19]. Therefore,
regarding the role of HAART, it remains to be clarified
whether persistent neuropsychological deficits are the
result of late-initiation of therapy, the use of lower CPE
rank regimens, ongoing low grade neuro-inflammation
or HAART-induced neurotoxicity.
The impact of HAART in a prospective study in South
Africa where clade C HIV is predominant has not been
reported. In this study, we hypothesized that individuals
initiating HAART would show improved neuropsychologi-
cal function over one year. Moreover, we hypothesized
that individuals with more severe disease at baseline
would have worse neuropsychological outcomes at one
year. Domain-specific changes were also explored.
Methods
Subjects
This study was conducted as part of a larger investiga-
tion of HIV-associated neurocognitive disorders
(HAND) in Cape Town, South Africa that has been
described previously [20]. In summary, we conducted
detailed neuropsychological assessments on 166 partici-
pants recruited from three primary health care centres.
At each visit, detailed socio-demographic and neurome-
dical measures were also administered and laboratory
tests completed. Participants were included if they were
soon to commence treatment with HAART according
to South African guidelines. They were excluded if they
had a severe psychiatric disorder (such as schizophrenia
or bipolar disorder), recent (within the last three
months) history of substance abuse, or significant neu-
rological disorder (such as epilepsy or significant head
injury defined as a loss of consciousness for more than
30 mins). We were able to re-assess 104 participants at
a one year follow-up assessment. Of this group, 22 did
not initiate HAART for the following reasons- one par-
ticipant had one month of treatment before being impri-
soned and defaulting. Of the remaining 21, 15 had CD4
cell counts above the guideline for initiation and were
not enrolled onto HAART. Their CD4 cell counts were
unknown at the time of initial study recruitment. The
other six participants qualified for HAART, and were
included in the study, but had not attended clinic
appointments during the one-year period and so were
not initiated on treatment.
Normative data for neuropsychological testing of isiX-
hosa-speaking participants was obtained from 120 HIV-
negative participants recruited from Voluntary Counsel-
ing and Testing services located at the same primary
care clinics. Other than being HIV negative, as con-
firmed by a recent rapid HIV test and confirmatory ser-
ological test, inclusion and exclusion criteria were
identical to the HIV-positive participants.
The CD4 cell counts were extracted from the labora-
tory records, linked by the participants’ clinic numbers.
Clade sequencing was not available on this sample but
more than 90% of infected individuals in the Cape
Town area are infected with clade C virus [21]. Hepatitis
sero-status was not established but the prevalence of
hepatitis C in South Africa is extremely low [22] The
use of HAART was also extracted post-hoc from clinical
records, and the CPE rank for each was calculated using
previously published criteria [14].
All participants who met study criteria and agreed to
participate provided written informed consent. Approval
to conduct the study was obtained from the Research
Ethics Committee of the Faculty of Health Sciences,
University of Cape Town, and from the relevant health
authorities.
Neuropsychological test battery
A neuropsychological test battery was administered to
all participants to assess specific domains of
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the domains: attention (the Mental Alternation Test
(MAT) and the Mental Control Test (MCT)), learning
and memory (the Hopkins Verbal Learning Test
(HVLT) and the Brief Visuospatial Memory Test
(BVMT)), psychomotor speed (Finger tapping (FT) and
the Grooved Pegboard Test (GP)), psychomotor speed
(Trail Making Test part A (TMTA), Color Trails Test 1
(CT1) and Digit Symbol-Coding (DSC)), executive func-
tion (Color Trails Test 2 (CT2), Stroop Colour-Word
test (SCW), Wisconsin Card-Sorting Test (WCST), and
language (category fluency)).
Determination of global neuropsychological function
Raw data from the above neuropsychological test battery
were converted to t-scores for each test using the demo-
graphically-adjusted normative data. From these, a defi-
cit score for each test was obtained using the methods
previously reported by Heaton and Carey [1,23]. The
deficit score ranges from 0 through 5. A score of 0 is
obtained for t-scores in the normal or superior range,
minimizing the effect of averaging out of impairments
i no t h e rd o m a i n s .T h i sp r o v i d e sam o r es e n s i t i v e
method for generating a summary neuropsychological
score than averaging neuropsychological scores. An
average global deficit score calculated (GDS) is then
obtained for each participant, with higher scores indica-
tive of greater impairment. GDS scores for participants
at baseline and follow-up were generated, and the
change in GDS calculated. GDS scores provide a contin-
uous measure of impairment with scores of > 0.5 pro-
viding high rates of specificity and positive predictive
value in establishing HIV-associated impairment. In
order to establish whether the degree of severity at base-
line was associated with demographic, clinical or disease
variables, we group the GDS into a non-impaired group
(scores < 0.25), a mild-moderately impaired group
(scores > 0.25 to < 0.75) and a severely impaired group
(scores > 0.75).
Statistical analysis
Data were analysed using STATA 11 (Stata Corporation,
Texas, USA). As data were not normally distributed
across all variables, we calculated medians and inter-
quartile ratios for the various cohort groups, and for the
GDS severity group. Comparisons were made using Wil-
coxon rank sum tests or Fisher Exact tests where appro-
priate. We generated line plots for the two time-points
of the three GDS HAART-treated groups, and compared
mean summary scores using Kruskal Wallis tests.
Impairment in individual domains (calculated as a GDS
score of ≥ 0.5) were used to generate rates of impair-
ment at baseline and follow-up. Differences in propor-
tions across the time-points were calculated using
McNemar’s chi-square test. We then evaluated linear
trends first using unadjusted models across the partici-
pants, with change in GDS between follow-up and base-
line as the dependent variable. We included
independent variables in a final multiple linear regres-
sion, if the simple model rendered a p-value of less than
0.1, or the variable was known to be strongly associated
with neuropsychological test performance. The final
model included gender, education, baseline and follow-
up CD4 cell count, and baseline GDS.
Results
A total of 166 participants were recruited into the
cohort study. Of these, 58 were not re-assessed at one
year for reasons including death (n = 9), migration (n =
6) and clinic loss-to-follow-up (n = 33). Of the 108 par-
ticipants retained and who completed neuropsychologi-
cal (NP) batteries at the two time points, 26 did not
receive HAART and were not included in the cohort
analysis. The three groups (non-retained, retained with
no HAART and retained with HAART) were compared
with respect to demographic and disease characteristics
and there were no significant differences across groups
(Table 1). Of note, there was no difference in their base-
line GDS score (p = 0.14).
Demographic, disease and neuropsychological charac-
teristics of participants initiating HAART across groups
of baseline GDS severity are presented in Table 2. The
mean change in GDS between assessments for all parti-
cipants was 0.13, and the improvement was highly sig-
nificant (p = .00). There were no differences across
groups for gender, home language, age, baseline CD4
count, duration of HAART or CPE. The groups differed
for level of education, with the groups of increasing
severity having a lower level of education (p = .00). The
groups also differed with respect to change in GDS,
with those more severely affected at baseline showing a
greater degree of change in GDS (p =. 0 0 ) .T h ee x t e n t
of GDS change is presented in Figure 1.
The rates of impairment across neuropsychological
domains at baseline and follow-up are shown in Figure
2. There were significant improvements in the propor-
tion of impairment for the domains of attention (p =
.01), verbal fluency (p = .00), motor speed (p =. 0 0 )a n d
executive functioning (p = .02). No improvement was
noted for learning (p = .83) and psychomotor processing
(p = .12). High rates of impairment persisted at one year
(range 23-45%).
Potential predictors of GDS change were examined
using a series of linear regression models. There were
significant unadjusted associations between male gender
(p = .01), having a lower level of education (p = .00),
baseline CD4 count (p = .04) and baseline GDS severity
(p = .00) with GDS change (Table 3). When these
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baseline GDS severity remained significantly associated
with GDS change (p = .00), while a lower level of educa-
tion neared significance in the model (p =. 0 5 ) .T h e
overall model was highly significant and provided a
moderate level of predictive value (p = .00; r-squared =
0.58). There was no effect of the duration of HAART or
CPE on GDS change. In order to investigate potential
associations between demographic and disease charac-
teristics on baseline GDS, we examined unadjusted asso-
ciations between these demographic and clinical
variables and baseline GDs severity. Only a lower level
of education was significantly associated with GDS (p =
.00; coefficient:-0.16; 96%CI:-0.22-0.10).
Discussion
We report on the first descriptive follow-up study con-
ducted among a group of patients utilizing a detailed
neuropsychological battery to establish the effects of
HAART in South Africa where clade C HIV is predomi-
nant. We found significant improvement in individuals
commencing HAART at one year follow-up. There was
improvement in most, but not all neuropsychological
domains, with high rates of impairment persisting.
Improvement in neuropsychological function was most
marked for those with a lower level of education and a
greater degree of impairment at baseline. Unadjusted
associations with GDS change were noted for male gen-
der, a lower level of education, lower baseline CD4
count and a greater baseline GDS severity. Individuals
most impaired at baseline were more likely to improve
at one year than those less impaired.
The use of HAART has frequently been reported as
improving neuropsychological outcomes in prospective
cohorts [3,13,24,25]. Predictors of improvement pre-
viously reported include higher CD4 count nadir, high
CPE, stability of HAART regimen, lower levels of base-
line impairment and good medication adherence [26,27].
All participants in this study had CD4 counts less than
200 cells/ml due to existing South African HAART
guidelines; this might account for high rates of impair-
ment at baseline, and to some extent, to persistence at
follow-up. It is possible that we did not detect an effect
for low CD4 count as the value range was limited to
119 to 215 in this cohort. We did not gather data on
nadir CD4 count specifically, although in most
instances, the value obtained at this pre-HAART visit is
the nadir. We did not detect an effect of different CPE
ranks, as first-line regimens, used by the majority of par-
ticipants in our study have moderate to high CPE ranks
(73 of 82 participants had a CPE rank ≥ 1.5). Also,
almost all participants achieved peripheral viral load
suppression during the first year of treatment, and
therefore were adequately immune reconstituted. This
suggests that they were also adherent to treatment.
There are few data enumerating changes in neuropsy-
chological performance by domain. Some have shown
improvements in psychomotor speed [12,28], while
others have reported either improvement in global
scores or across multiple domains [29-31]. While we
Table 1 Demographic, disease and neuropsychological characteristics of all participants from baseline
Non-retained (n = 58) Retained no HAART (n = 26) Retained with HAART (n = 82) p-value
CD4 baseline median (IQR) 165 (84-218) 192 (172-329) 166 (119-211.5) 0.1
Women (%) 40 (70) 19 (73) 64 (78) 0.58
isiXhosa 46 (81) 24 (83) 75 (91) 0.48
Age median (IQR) 30 (27-32) 30 (27-33) 29.5 (27-32) 0.39
Education median (IQR) 10 (9-11) 10 (9-11) 10-9-12) 0.69
Baseline total GDS median (IQR) 0.67 (0.27-1.33) 0.5 (0.27-1.0) 0.47 (0.13-0.93) 0.14
Table 2 Characteristics of participants with HAART over one year grouped by total GDS severity
GDS Groups
123 p-value
Number Women (%) 21 (80.7) 21 (84) 21 (67.7) 0.34
Number isiXhosa (%) 22 (88.5) 23 (95.7) 30 (96.8) 0.22
Age median (IQR) 30 (27-31) 28 (25-32) 30 (28-32) 0.34
Education median (IQR) 12 (10-12) 10 (10-12) 9 (8-10) 0.00*
CD4 One median (IQR) 180 (146-199) 182.5 (143-221) 138 (100-205) 0.32
CD4_Two median (IQR) 395 (271-465) 340 (263-518) 302 (156-388) 0.07
Duration of HAART in months median (IQR) 11 (10-12) 11 (10-14) 10 (8-12) 0.45
CPE median (IQR) 2 (1.5-2.5) 2 (1.5-2.25) 2 (1.5-2.5) 0.98
GDS Change median (IQR) 0 (-0.67-0.67) 0.13 (-0.67-0.27) 0.6 (0.2-0.8) 0.00*
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tion, we did not observe this for learning or psychomo-
tor processing. The domain of learning and
psychomotor processing has been held to be a core fea-
ture of HIV-associated neurocognitive impairment, due
to its predilection for the deep grey nuclei [32]. The
absence of significant improvement suggests that HIV-
associated disease is either established earlier and
therefore less amenable to reversal by HAART in late
stage/low CD4 nadir disease; or that neuro-inflamma-
tion is ongoing in these brain regions; or lastly, that
HAART is not effective in these areas due to deficient
penetration or a direct drug toxicity.
In the neuropsychology literature, improvement is
usually associated with less baseline impairment [33].
We noted the converse, that more severe baseline
Figure 1 Change in Global Deficit Score at baseline and one year of participants initiating HAART across groups of severity at
baseline (n = 82). Mean change: GDS 1 = 0.01; GDS 2 = 0.06; GDS 3 = 0.24. Kruskal Wallis p-value = 0.00. Percent neuropsychological
impairment over one year by domain. Black bars: Baseline data; Hatched bars: One year data.
Figure 2 Percent neuropsychological impairment over one year by domain. Black bars: Baseline data; Hatched bars: One year data
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greater degree of GDS change was significantly asso-
ciated with male gender, a lower level of education,
baseline CD4 cell count, baseline GDS severity and
neared significance with follow-up CD4 cell count (p =
0.05). Only baseline GDS severity remained significant
in adjusted models, while a lower level neared signifi-
cance (p = 0.05). The strong trend to improvement in
those most severely affected likely is explained by the
range of possible improvement being wider; those with
less impairment probably experienced a ceiling effect on
their ability to improve. The improvement shown by
individuals with less education in the adjusted model
suggests that this effect was present together with the
degree of impairment. This effect may be explained by
participant characteristics such as test experience,
whereby individuals with lower education benefitted
more from the experience of being tested. In South
Africa, the effects of quality of education, as opposed to
levels of education, have been shown to exert effects in
test settings [34].
It is less well understood whether improvement in
cohort studies is associated only with a HAART effect,
or is also associated with practice effect, test familiarity
or other participant characteristics, such as level and
quality of education [32,4]. We re-assessed participants
after one year to reduce practice effect, although some
degree of familiarity with test environment and adminis-
tration may have had an impact on improvement. When
we investigated the associations of baseline GDS, we
noted only lower education to be a significant predictor.
In this cohort, the medians across the GDS severity
groups ranged from 9-12 years which might have had a
substantial effect on performance.
Conclusions
Several limitations of our study warrant discussion. We
were able to retain a smaller sample of participants than
originally recruited. The significant drop-out rate is due
to a combination of factors, including large patient
numbers at primary care clinics making tracking and
retention by services difficult, mortality during early
treatment, and migration of individuals. We also did not
include additional groups of differently defined HIV
positive participants who may have acted as controls.
Such groups may have allowed for comparison of possi-
ble practice effects. These control groups may have
included participants on stable HAART regimens, or
those who were not. In the latter case, it would not be
ethical to withhold treatment from individuals who met
criteria for HAART. This group would therefore by defi-
nition have a different set of disease characteristics. We
did not perform HIV subtype analysis on this sample,
which would have allowed us to draw clearer conclu-
sions about the putative role of clade in neuropathogen-
esis. Also, we were not able to obtain CSF in order to
characterize intra-thecal viral load or inflammatory mar-
kers. The use of lumbar for research has not been
approved widely in our setting. Lastly, we did not con-
trol for the range of baseline neuropsychological impair-
ments we detected. The inclusion of a non-impaired
group in measurement of change does affect group dif-
ferences and outcomes.
We believe that this study makes an important contri-
bution to our understanding of the effect of HAART on
neuropsychologically impaired individuals, in South
Africa, where clade C HIV is highly prevalent. This ben-
efit seemed to accrue most to individuals with more
severe baseline impairment. Studies with larger compari-
son groups, and where HIV disease characteristics are
similar, are needed to establish whether the trends we
identified are clinically meaningful.
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